Pacific Edge's Medicare Coverage Review Extension

Pacific Edge (ASX: $PEB) has received confirmation that Novitas, the Medicare Administrative Contractor (MAC) overseeing its US lab, has been granted an extension to finalize or withdraw the Local Coverage Determination (LCD) 'Genetic Testing for Oncology' (DL 39365). The extension means that the company's Cxbladder tests continue to receive reimbursement from Medicare and Medicare Advantage payers in line with historical rates, subject to medical necessity guidelines.

Executive Commentary on Medicare Coverage Review Extension

Pacific Edge continues to expect Novitas to finalize the LCD, but the timeframe is currently unknown. The company will update shareholders as it gains certainty on the status of the LCD and the timeline for its resolution, but will not be making further comment on the matter until then. This extension allows for thorough consideration of feedback from interested parties regarding the Genetic Testing for Oncology LCD, and future updates will be published to the Medicare Coverage Database.

Summary of Medicare Coverage Review Extension

Pacific Edge (ASX: $PEB) has noted the extension granted to Novitas for the Local Coverage Determination (LCD) 'Genetic Testing for Oncology' (DL 39365), which impacts Medicare coverage of its Cxbladder tests. The company's tests Cxbladder Triage, Detect, and Monitor continue to receive reimbursement from Medicare and Medicare Advantage payers in line with historical rates, subject to medical necessity guidelines. Pacific Edge anticipates Novitas to finalize the LCD, and will provide updates to shareholders as more information becomes available. The company remains committed to the development and commercialization of bladder cancer diagnostic and prognostic tests, aiming to improve patient health outcomes.